1.AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-IIIb DIALIZE Study to Treat Hyperkalaemia in Patients with End-Stage Renal Disease

Published: Jun 14, 2019 | Tags: AstraZeneca, Reports, Results, Lokelma, sodium zirconium cyclosilicate, P-IIIb, DIALIZE Study, Treat, Hyperkalaemia, End-Stage Renal Disease

2. Upsher-Smith Signs an Agreement with Dr. Reddy's Laboratories to Acquire its Two Neurology Products

Published: Jun 14, 2019 | Tags: Upsher-Smith, Signs, Agreement, Dr. Reddy’s Laboratories, Acquires, Neurological Products

3. Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Published: Jun 14, 2019 | Tags: Eli Lilly, Reports, Positive, Results, Taltz, ixekizumab, P-IIIb/IV, SPIRIT-H2H Study, Active Psoriatic Arthritis, #EULAR2019

4. BeiGene Reports Updated Results of Tislelizumab in P-II Study in Chinese Patients with R/R Classical Hodgkin Lymphoma #EHA2019

Published: Jun 14, 2019 | Tags: BeiGene, Reports, Updated, Results, Tislelizumab, P-II, Study, Chinese Patients, R/R, Classical Hodgkin Lymphoma, #EHA2019

5. BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Published: Jun 13, 2019 | Tags: BMS, Reports, Data, Orencia, abatacept, P-IV, Early AMPLE, Study, Moderate, Severe, Rheumatoid Arthritis, #EULAR20196

6.Amgen and Allergan's Kanjinti (trastuzumab, biosimilar) Receive the US FDA's Approval for All Approved Indications of Herceptin

Published: Jun 13, 2019 | Tags: Amgen, Allergan, Kanjinti, trastuzumab, biosimilar, Receive, FDA, Approval, Approved, Indications, Herceptin

7.Sobi Acquires Novimmune's Emapalumab with its All Related Assets to Strengthen its Focus in Hematology and Immunology

Published: Jun 12, 2019 | Tags:Sobi, Acquires, Novimmune, Emapalumab, Related Assets, Hematology, Immunology

8.Celltrion Reports Results of CT-P13 SC (infliximab, biosimilar) in a Clinical Study for Rheumatoid Arthritis #EULAR2019

Published: Jun 11, 2019 | Tags: Celltrion, Reports, Results, CT-P13 SC, infliximab, biosimilar, Clinical Study, Rheumatoid Arthritis, #EULAR2019

9. Pfizer Reports Results of Xeljanz XR (tofacitinib) in the P-IIIB/IV ORAL Shift Study for Moderate to Severe Rheumatoid Arthritis #EULAR2019

Published: Jun 12, 2019 | Tags: Pfizer, Reports, Results, Xeljanz XR, tofacitinib, P-IIIB/IV, ORAL Shift, Study, Moderate, Severe Rheumatoid Arthritis, #EULAR2019

10. Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris

Published: Jun 12, 2019 | Tags: Genentech, Reports, Positive, Results, Rituxan, rituximab, P-III, PEMPHIX Study, Treat, Patients, Moderate, Severe, Pemphigus Vulgaris

11.AbbVie Reports Results of Upadacitinib in Two P-III Studies for Rheumatoid Arthritis #EULAR2019

Published: June 12, 2019 | Tags: AbbVie, Reports, Results, Upadacitinib, Two, P-III, Studies, Rheumatoid Arthritis, #EULAR

12. Novo Nordisk Reports Cardiovascular Outcomes of Oral Semaglutide in PIONEER 6 Study for Type 2 Diabetes

Published: June 11, 2019 | Tags: Novo Nordisk, Reports, Cardiovascular Outcomes, Oral Semaglutide, PIONEER 6, Study, Type 2 Diabetes

13. Genentech Reports Acceptance of sBLA for Rituxan (rituximab) to Treat Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children with 2 Years and Older

Published: June 11, 2019 | Tags: Genentech, Reports, Acceptance, sBLA, Rituxan, rituximab, Granulomatosis Polyangiitis, Microscopic Polyangiitis, Children, 2 Years, Older

14. Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio at European Congress of Rheumatology (EULAR) 2019

Published: June 11, 2019 | Tags: Biogen, Reports, New Data, Biosimilar, Anti-TNF, Portfolio, European Congress of Rheumatology, 2019

15.Janssen Reports Cardiovascular Outcomes of Invokana (canagliflozin) in P-III CREDENCE Study for Type 2 Diabetes and Chronic Kidney Disease

Published: June 11, 2019 | Tags: Janssen, Reports, Cardiovascular Outcomes, Invokana, canagliflozin, P-III, CREDENCE, Study, Type 2, Diabetes, Chronic Kidney Disease

16.Janssen Signs an Exclusive Worldwide License and Option Agreement with Genmab for its HexaBody-CD38

Published: June 11, 2019 | Tags: Janssen, Signs, Exclusive, Worldwide, License, Option, Agreement, Genmab, HexaBody-CD38

17. Merck's Keytruda (pembrolizumab) Receives FDA's Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Published: June 11, 2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, 1L, Treatment, Metastatic, Unresectable, Recurrent, Head and Neck Squamous Cell Carcinoma

18. Eli Lilly and Boehringer Ingelheim Report Cardiovascular Outcomes of Tradjenta (linagliptin) in CAROLINA Study for Type 2 Diabetes

Published: June 10, 2019 | Tags: Eli Lilly, Boehringer Ingelheim, Report, Cardiovascular Outcomes, Tradjenta, linagliptin, CAROLINA, Study, Type 2, Diabetes

19. Abbvie Reports Two Years Data of Skyrizi (risankizumab) in P-III IMMhance Study for Moderate to Severe Plaque Psoriasis #WCD2019

Published: June 11, 2019 | Tags: Abbvie, Reports, Two Years, Data, Skyrizi, risankizumab, P-III, IMMhance, Study, Moderate, Severe, Plaque Psoriasis, #WCD2019

20. Innovative Health Solution's IB-Stim Receives FDA's Clearance for the Treatment of Functional Abdominal Pain in Irritable Bowel Syndrome

Published: June 11, 2019 | Tags: Innovative Health Solution, IB-Stim, Receives, FDA, Clearance, Treatment, Functional Abdominal Pain, Irritable Bowel Syndrome

21. Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

Published: June 11, 2019 | Tags: Eli Lilly, Reports, Results, Taltz, ixekizumab, 5 Years, P-III, Study, Plaque Psoriasis, #WCD2019

22.Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma

Published: June 11, 2019 | Tags: Roche, Polivy, polatuzumab vedotin-piiq, Combination, Therapy, Receives, FDA, Accelerated, Approval, Relapsed, Refractory, Lymphoma

23. Medtronic and Tidepool Collaborates to Develop Interoperable Automated Insulin Pump System for Diabetes Management

Published: June 07, 2019 | Tags: Medtronic, Tidepool, Collaborates, Develop, Interoperable Automated Insulin Pump System, Diabetes Management

24. Merck To Acquire Tilos Therapeutics for ~ $773M

Published: June 10, 2019 | Tags: Merck, Acquire, Tilos Therapeutics, $773M

25. Theramex Signs an Exclusive License Agreement with Therapeutics MD to Commercialize Bijuva and Imvexxy Outside the US

Published: June 07, 2019 | Tags: Theramex, Signs, Exclusive, License, Agreement, Therapeutics MD, Commercialize, Bijuva, Imvexxy, Outside, US

26.Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes

Published: June 06, 2019 | Tags: Eli Lilly, Reports, Results, Ultra Rapid Lispro, URLi, Two, Studies, Type 1, Type 2, Diabetes